ACADIA Pharmaceuticals Beats Q2 Earnings by 200% as Citigroup Hikes Target

Key Facts

1ACADIA Pharmaceuticals reported Q2 earnings of $0.18 per share, significantly beating the $0.06 estimate.

2Citigroup raised its price target for ACADIA from $35 to $39 while reiterating a Buy rating.

3Company revenue rose 16% year-over-year to $307.96 million, driven by sales of Daybue and Nuplazid.

In a move reflecting the strong operational performance of the biopharmaceutical sector, ACADIA Pharmaceuticals announced exceptional financial results for the second quarter of 2026. The company reported earnings of $0.18 per share, representing a 200% positive surprise compared to analyst estimates of $0.06. According to reports, company revenue rose 16% year-over-year to reach $307.96 million, primarily driven by a 30% increase in sales for Daybue and a 9% growth in Nuplazid sales.

Following these robust results, Citigroup raised its price target for ACADIA stock to $39 from $35 while reiterating a Buy rating, reflecting optimism regarding the company's future market valuation. Additionally, the company raised its full-year 2026 revenue guidance to a range of $1.24 billion to $1.30 billion. These developments come as financial data showed realized revenues surpassed analyst predictions by 4.81%, strengthening the firm's position within the pharmaceutical industry.

Regarding price action, specific closing price data for today was unavailable, but the qualitative trend remains bullish supported by major institutional upgrades. Investors should monitor upcoming U.S. economic catalysts, such as Factory Orders and the ISM Services PMI scheduled for August 5, 2026, as these macro indicators may influence risk appetite across the biotechnology sector and broader U.S. equities.

Sources:

Financial Modeling Prep